닥플 플러스
2026 대한위장관외과학회 연수강좌
대한외과학회
연수평점 :5점
오프라인
주관
대한외과학회 / 대한위장관외과학회
교육일자
2026-08-29
수강료
20,000원
교육형태
오프라인
등록일시
2026-07-24
교육시간
5시간 15분
연수평점
5점
장소
서울특별시 고려대학교 의과대학 본관 2층 유광사홀
교육종류
외과
타임테이블
| 날짜 | 시간 | 강의명 | 강사 | 구분 |
|---|---|---|---|---|
| 2026-08-29 | 09:30~09:45 | Navigating Resectable Gastric Cancer: From Laparoscopic Gastrectomy to Adjuvant Chemotherapy | 서윤석(서울의대) | - |
| 2026-08-29 | 09:45~10:00 | Surgical Techniques and Outcomes in Conversion Surgery for Advanced Gastric Cancer | 정성아(울산의대) | - |
| 2026-08-29 | 10:00~10:15 | Precision MIS after Neoadjuvant Therapy: Optimal Timing and Technical Mastery for AGC | 이창민(고려의대) | - |
| 2026-08-29 | 10:15~10:30 | Discussion | - | - |
| 2026-08-29 | 10:30~10:50 | Break | - | - |
| 2026-08-29 | 10:50~11:05 | Chemotherapy in Gastric Cancer: Global Guidelines vs. National Reimbursement Standards | 김기윤(성균관의대) | - |
| 2026-08-29 | 11:05~11:20 | Strategic Roadmap and Progress Report of the Clinical Practice Guideline TFT | 윤종혁(순천향의대) | - |
| 2026-08-29 | 11:20~11:35 | Academic Legacy and Future Vision of the SOF | 권인규(연세의대) | - |
| 2026-08-29 | 11:35~11:50 | Discussion | - | - |
| 2026-08-29 | 11:50~12:20 | Redefining First-line Treatment in Advanced Gastric Cancer: The Clinical Value of Tislelizumab | 김윤홍(고신의대) | - |
| 2026-08-29 | 12:20~13:20 | Lunch | - | - |
| 2026-08-29 | 13:20~13:50 | Earlier Systemic Control, Better Curative Intent: The Clinical Value of MATTERHORN | 박우찬(서울의대) | - |
| 2026-08-29 | 13:50~14:05 | Clinical Algorithms for irAEs: When to Suspect, Interrupt, and Initiate Steroids | 남궁윤(고려의대) | - |
| 2026-08-29 | 14:05~14:20 | Strategic Management of Targeted Therapy Side Effects: Focus on Trastuzumab (and Deruxtecan), Zolbetuximab and Ramucirumab | 박영규(건양의대) | - |
| 2026-08-29 | 14:20~14:35 | Maintaining Cancer Therapy Through Effective Toxicity Management: An Oncology APN Perspective | 김민경(단국대병원) | - |
| 2026-08-29 | 14:35~14:50 | Discussion | - | - |
| 2026-08-29 | 14:50~15:10 | Break | - | - |
| 2026-08-29 | 15:10~15:25 | Clinical Experience of Single Nivolumab as Third-Line Treatment for Advanced Gastric Cancer | 박재균(부산의대) | - |
| 2026-08-29 | 15:25~15:40 | Therapeutic Outcomes of Pembrolizumab Maintenance Therapy in HER2-Negative Advanced Gastric Cancer | 서지원(가톨릭의대) | - |
| 2026-08-29 | 15:40~15:55 | Emerging Targeted Therapy in Claudin 18.2-Positive Gastric Cancer: A Case of Zolbetuximab Treatment | 송정호(아주의대) | - |
| 2026-08-29 | 15:55~16:10 | Synergy of Trastuzumab and Pembrolizumab in HER2-Positive Advanced Gastric Cancer: Case Analysis | 정지은(연세의대) | - |
| 2026-08-29 | 16:10~16:25 | Discussion | - | - |
비고
사전등록) 전문의 2만원현장등록) 전문의 2만원
문의처
담당자
차진주
연락처
02-459-8284
이메일
society@medioffice.or.kr